Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Science"
DOI: 10.1111/cts.13296
Abstract: Propafenone is an antiarrhythmic drug metabolized primarily by cytochrome P450 2D6 (CYP2D6). In adults, propafenone adverse events (AEs) are associated with CYP2D6 poor metabolizer status; however, pediatric data are lacking. Subjects were tested for 10… read more here.
Keywords: genetic variation; cyp2d6 genetic; cyp2d6; propafenone ... See more keywords
Influence of CYP2D6*5 and *10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13155
Abstract: Nebivolol, a selective β1 adrenoreceptor antagonist, is predominantly metabolized by cytochrome P450 (CYP)2D6 and shows a wide interindividual variability in pharmacokinetics. The present study was conducted to evaluate the effects of the major CYP2D6 polymorphisms… read more here.
Keywords: healthy chinese; cyp2d6 polymorphism; pharmacokinetics nebivolol; polymorphism pharmacokinetics ... See more keywords